Tian Zhang, MD, Associate Professor, Department of Internal Medicine, UT Southwestern Medical Center, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy, as well as available options after recurrence on second-line therapy.
Post Tags:ASCO GU 2023-Renal Cell Carcinoma
Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.